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Inflammatory memories: Is epigenetics the missing link to
persistent stromal cell activation in rheumatoid arthritis?
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction. Synovial
fibroblasts are recognized as key cells in the pathogenesis of RA since they attract and activate immune
cells and produce matrix degrading enzymes. Most notably synovial fibroblasts from patients with RA
are stably activated and produce high levels of disease-promoting molecules without further stimulation
by immune cells. Accumulating data suggest that epigenetic changes in stromal cell populations might
be crucially involved in the pathology of RA and other chronic inflammatory diseases. In the current
review, we discuss the mechanisms by which epigenetic changes might cause the stable activation of
synovial fibroblasts in RA and how changes in the epigenome might alter immune function and
inflammatory response and thereby promote the development of chronic diseases.
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ABSTRACT 
Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction. 
Synovial fibroblasts are recognized as key cells in the pathogenesis of RA since they attract 
and activate immune cells and produce matrix degrading enzymes. Most notably synovial 
fibroblasts from patients with RA are stably activated and produce high levels of disease-
promoting molecules without further stimulation by immune cells. Accumulating data suggest 
that epigenetic changes in stromal cell populations might be crucially involved in the 
pathology of RA and other chronic inflammatory diseases.  In the current review, we discuss 
the mechanisms by which epigenetic changes might cause the stable activation of synovial 
fibroblasts in RA and how changes in the epigenome might alter immune function and 
inflammatory response and thereby promote the development of chronic diseases. 
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1. Introduction 
In recent years, understanding of the pathogenesis of rheumatoid arthritis (RA) increased 
exponentially, leading to the development of novel targeted therapies as well as to changes in 
general treatment strategies. At the same time however, it became clear that the pathogenesis 
of RA is highly complex. Studies showing the presence of auto-antibodies and increased 
levels of cytokines and chemokines years before the first clinical symptoms clearly 
demonstrated that the disease is already far advanced when joint destruction starts and 
increased the awareness that even at the onset of symptoms irreversible damage of articular 
structures is imminent [1, 2]. It is now known that the genetic background, environmental 
influences, aberrant activation of the innate immune system as well as antigen-driven T and B 
cell responses are of importance. However it is not clear how and whether these different 
aspects are linked to cause disease. Furthermore, it still unknown why the synovium is 
primarily affected and which factors lead to the pathognomonic symmetric localization of 
joint involvement.  
Up to now two distinct subsets of RA are discerned, namely RA positive for anti-citrullinated 
peptide antibodies (ACPA) and ACPA negative disease. These RA subtypes do not only 
differ in their clinical course but also in their underlying mechanisms. Smoking for instance 
has been shown to mainly increase the risk to develop ACPA positive RA [3]. Interestingly, 
this risk is much higher in individuals carrying shared epitope alleles providing evidence for a 
strong gene-environment interaction in this subgroup of patients [4, 5]. Apart from the shared 
epitope a variety of different allelic variants have been found to influence disease 
susceptibility and outcome alone or in combination, but direct connections between gene 
polymorphisms and pathogenetic pathways are elusive. Furthermore, most of the risk loci 
found up to now are not specific for RA and seem to generally increase the risk for 
autoimmunity pointing to additional factors triggering disease onset [6]. As recently 
highlighted by a special issue of the Journal of Autoimmunity, epidemiological studies gave 
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new insights which and how environmental factors might influence the development and the 
course of RA [7]. In particular, epigenetic changes could be identified as an important link 
between the environment and changes in gene expression. 
Studies analysing the role of synovial fibroblasts in RA (RASFs) have significantly 
contributed to the overall understanding of local processes in joint destruction and chronic 
synovitis in RA, as RASFs not only strongly respond to a pro-inflammatory environment, but 
also actively and autonomously drive joint inflammation and destruction.  They do so by 
producing a variety of pro-inflammatory cytokines, chemokines and matrix degrading 
enzymes. Most notably, RASFs appear to have a stably imprinted, activated phenotype when 
compared to healthy synovial fibroblasts. These features not only make RASFs an attractive 
target for future therapeutics but also give us the opportunity to learn more about local 
pathogenic pathways in RA.   
 
2. Synovial fibroblasts: key cells of joint destruction in Rheumatoid Arthritis 
2.1 Activation of RASFs  
The pro-inflammatory environment in RA joints including high levels of cytokines, growth 
factors and infiltrating inflammatory cells strongly activates RASFs. The best studied 
activators of RASFs are TNF-α and IL-1 which are mainly produced by macrophages. In 
addition, RASFs express a variety of intra-and extracellular pattern-recognition receptors 
which allows them to react to environmental danger signals and make them important effector 
cells of the innate immune system. The Toll-like receptors (TLRs) 1-6, as well as the 
intracellular Nod-like receptor NOD2, are expressed and functional in RASFs and induce 
activation of NF-κB and mitogen-activated protein kinases (MAPKs) [8, 9]. Each of these 
pattern-recognition receptors recognizes different conserved pathogen-associated molecular 
patterns (PAMPs) derived from bacteria, virus, fungi or protozoa, and induces an immune 
response against these infectious agents. Even though an infectious trigger for the 
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development RA has not been found, bacterial DNA and peptidoglycans were shown to be 
retained in arthritic joints, which might lead to constant activation of TLR pathways [10]. 
Interestingly, TLRs were not only described to bind PAMPs but also to react to damage-
associated molecular patterns (DAMPs) that are commonly increased after tissue injury. A 
variety of DAMPs have been found to be elevated in the joints of RA patients and via 
activation of TLRs might lead to perpetuation of the chronic inflammatory and destructive 
process. For instance, the extracellular matrix glycoprotein tenascin-C and the DNA binding 
protein HMGB1 are both elevated in RA and provoke a pro-inflammatory response via TLR 
signalling [11-13]. Also, double-stranded RNA from necrotic cells has been shown to induce 
the expression of IL-6 and MMPs in RASFs via TLR3 [14]. 
 
2.2 The imprinted phenotype of RASFs 
RASFs not only strongly respond to a pro-inflammatory environment, they also actively and 
autonomously drive joint inflammation and destruction. RASFs appear to have a stably 
imprinted, activated phenotype when compared to healthy synovial fibroblasts [15]. This 
phenotype of RASFs is impressively demonstrated in experiments where RASFs are co-
implanted with normal human cartilage under the kidney capsule of severe combined 
immunodeficient (SCID) mice. Isolated RASFs, despite several passages in culture, but not 
osteoarthritis (OASFs) or healthy synovial fibroblasts deeply invade the co-implanted 
cartilage in the absence of other inflammatory cells [16]. Continuing work with this model 
recently showed that RASFs can migrate via the bloodstream to implanted cartilage at a 
distant site [17]. This remarkable migratory potential of RASFs might partly explain the poly-
articular affection which is typically found in RA patients. Even though overall evidence has 
been accumulated that synovial fibroblasts in RA differ in their phenotype from normal 
synovial fibroblasts and that these changes in behaviour are imprinted and stable over several 
passages in culture, the mechanisms behind this altered phenotype remain as yet elusive. 
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3. Epigenetics 
3.1 Histone modifications and DNA methylation 
Histone tails are modified by methylation, acetylation, phosphorylation, ubiquitinylation, 
SUMOylation and poly-ADP-ribosylation. All of these different histone modifications can be 
placed at various sites of the histone tails and together compose a complex histone code 
which confers transcriptional repression or activation for a specific genomic site [18].  
Histone deacetylases (HDACs) are the group of enzymes that remove acetyl groups from 
histone tails which leads to condensation of chromatin structures and repression of gene 
expression. Counterregulatory to HDACs, histone acetyl transferases (HATs) acetylate 
histone tails. However, histones are not the only substrates for HDACs and HATs. Also 
transcription factors such as NF-κB or STATs are acetylated and deacetylated by HATs and 
HDACs. Deacetylation of STAT1 by HDAC3 for instance is a prerequisite for its 
phosphorylation and proper activation. This effect is reversed by the CREB binding protein 
(CBP)/p300 which acetylates STAT1 and thereby inhibits STAT1 signaling [19].  
Modification of DNA by DNA methyltransferases (DNMTs) is an important mechanism to 
shape the gene expression pattern of a cell according to its environment. DNMTs add methyl 
groups to cytosines mainly at sites with a high content of guanine and cytosines, so-called 
CpG islands. Methylation of CpG islands in gene promoters leads to gene silencing via 
inhibition of transcription factor binding or via attraction of transcriptional repressors. During 
development, DNA methylation regulates the expression of tissue specific genes, represses 
the expression of repetitive sequences such as retrotransposons and mediates inactivation of 
the silent X chromosome in female cells. Loss of methylation in oncogenes and aberrant 
hypermethylation in tumor suppressor genes has been found to contribute to cancer growth 
and metastasis. 
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Strictly speaking epigenetic changes are changes in gene function that are heritable over 
generations without altering the DNA sequence. However short lived chromatin modifications 
can also substantially alter gene function and thereby indirectly initiate heritable epigenetic 
changes of the genome. Therefore the definition of epigenetics today is loosened to include 
not only classical epigenetic changes such as methylation of DNA and histone tails, but also 
more transient changes such as histone acetylation and phosphorylation [20]. Epigenetic 
mechanisms recently raised great interest in the study of the pathogenesis of chronic diseases. 
Since epigenetic changes seem to register and perpetuate alterations in cellular activity, they 
might not only explain lack of inflammatory resolution but also the connection between 
environmental risk factors and disease onset. The formation of an international epigenetic 
autoimmune group during the 10th International Symposium on Sjögren’s Syndrom in 2009 
reflects the great interest that epigenetics also raised in the study of autoimmune diseases [21]. 
More and more evidence accumulates that histone modifications and DNA methylation can 
influence immune function and contribute to the development of autoimmunity. Modification 
of the epigenome have been found in systemic lupus erythematodes (SLE), multiple sclerosis, 
Sjögren’s Syndrome, systemic sclerosis and RA (compiled in [22]).  
 
3.2 Histone modifications in RA 
In RA, analysis of epigenetic changes is still in its early stages, but some interesting insights   
about how epigenetics might contribute to the pathogenesis of RA have already been provided. 
Changes in the expression and activity of histone deacetylases (HDACs), which in addition to 
modifying histone tails can negatively regulate gene promoter access, have been reported by 
Huber and colleagues.  They observed decreased HDAC activity in RA synovial tissues 
compared to OA synovial tissues with decreased levels of HDAC1 and HDAC2, suggesting a 
global increase in histone and non-histone acetylation [23]. However, Kawabata et al have 
found that HDAC activity is higher in the synovial tissues of RA patients than in OA patients 
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and HDAC1 expression was increased, which would lead to a deacetylated state in RA [24]. 
Although data is limited, it has been speculated that these differences might stem from 
differences in the medical treatment of the studied patients [25].  Up to now it is not clarified 
whether in RA the scale is tipped towards hyper- or hypoacetylation, but an 
immunohistochemical study with antibodies against acetyl-lysine showed strong acetylation 
in macrophages and RASFs in RA synovial tissues [25].  
In contrast to uncertainties about potential changes in global histone acetylation, enhanced 
histone acetylation at promoters of specific genes relevant to pathology in RA has been 
observed.  Changes in histone acetylation were linked to high levels of the small ubiquitin-
related modifier SUMO-1 in RASFs. Histone acetylation in the matrix-metalloproteinase 1 
(MMP1) promoter was increased in RASFs compared to OASFs, but could be normalized by 
enforced expression of the sentrin-specific protease SENP1 which cleaves SUMO-1 [26]. 
Accordingly, SENP1 overexpression downregulated expression levels of MMP-1. Since this 
effect was dependent on the expression of HDAC4 the authors hypothesized that increased 
SUMOylation of HDAC4 in RASFs prevents its nuclear translocation and subsequent 
deacetylation of histones at the MMP-1 promoter. Since acetylation of histones is a general 
mechanism that keeps the expression of genes turned on, it can be assumed that this 
mechanism does not only influence the expression of MMP-1 but might be responsible for the 
increased expression of a variety of other genes in RASFs. 
Alternatively, strategies aimed at decreasing HDAC function may have therapeutic 
possibilities in RA, since administration of different HDAC inhibitors has shown promising 
results in arthritis animal models [27-29]. Also, in vitro treatment of RA macrophages and 
synovial explants showed potent anti-inflammatory actions of HDAC inhibitors [30]. The 
mechanisms by which HDAC inhibitors promote anti-inflammatory effects are not completely 
understood, but could stem from enhanced acetylation of histones at the promoters of 
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transcriptional repressors, enhanced transcription of anti-inflammatory gene products, or 
modification of non-histone targets [31]. 
 
3.3 Changes of DNA methylation in RA 
Evidence of disturbed patterns of DNA methylation has been found in RA. Aberrant 
expression of the retrotransposon LINE-1 (long interspersed nucleotide elements–1) in RASF 
but not OASF suggests specific promoter demethylation in RA [32, 33]. Retrotransposons are 
mobile DNA sequences which can relocate within the genome, but are normally silenced by 
DNA methylation. The LINE-1 retrotransposon is one of the most common retrotransposons 
found in the human genome. Expression of LINE-1 elements in RASFs induces transcription 
of p38δ, galectin-3 binding protein, and the met protooncogene, demonstrating that the 
presence of functional LINE-1 can induce changes in gene expression [32]. The hypothesis 
that expression of LINE-1 in RASFs was due to loss of methylation marks in RA was 
corroborated by the finding that compared to OASFs or healthy synovial fibroblasts, genomic 
DNA of RASFs was globally hypomethylated [34]. Furthermore, it could be shown that while 
OASFs normally increased their levels of the DNA methyltransferase DNMT1 during 
proliferation, thereby assuring proper restoration of methyl marks in the newly synthesized 
DNA strand, proliferating RASFs showed a relative lack of DNMT1. This deficiency of 
DNMT1 might cause a loss of methylation marks in daughter cells, leading to progressive 
changes in the phenotype of RASFs over time.  
Up to now only a few studies have analyzed and identified specific promoter regions that are 
differentially methylated in RASFs versus OASFs. The constitutively increased expression of 
CXCL12 by RASFs for instance, could be shown to be due to relative hypomethylation of its 
promoter region in RASFs compared to OASFs and healthy synovial fibroblasts [35]. High 
CXCL12 levels in turn stimulate production of MMPs, a mechanism that might partly be 
responsible for the destructive behaviour of RASFs in the SCID mouse co-implantation model 
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and in human patients. In line with epigenetic mechanisms regulating CXCL12 production in 
RASFs, in RA patients treated with TNF blocking agents levels of CXCL12 remain high and 
a low grade disease activity persists, whereas after synovectomy CXCL12 is significantly 
reduced [36, 37]. 
Similar to findings in tumor cells, not only hypomethylation but also hypermethylated 
promoter regions were detected in RA. A specific CpG island in the promoter of death 
domain receptor 3 (DR-3) was shown to be hypermethylated in RASFs and accordingly 
expression of DR-3 was decreased in RASFs compared to OASFs [38]. Interestingly, also in 
PBMCs and T cells from RA patients disturbances of DNA methylation could be detected 
[39]. Particularly, in RA PBMCs loss of methylation in the promoter of the IL-6 and the 
ephrinB1 gene was found to be connected to increased expression of these genes in RA [40, 
41]. 
It is not clear yet how broadly changes in DNA methylation patterns affect the phenotype of 
RASFs. In the human genome, primarily sequences outside of promoters are strongly 
methylated, while around 95% of CpG islands in promoter regions are demethylated [42]. The 
global hypomethylated state of DNA in RASFs would therefore mainly affect non-regulatory 
sequences such as retrotransposons and repetitive sequences, coding DNA and intergenic 
DNA. Intriguingly, around 50% of the genes coding for microRNAs have been found to be 
controlled by DNA methylation, and in tumor cells aberrant hyper- as well as 
hypomethylation of microRNA genes is detectable [43]. MicroRNAs are small non-coding 
RNAs that modulate gene expression by degradation of target mRNA or by inhibition of 
protein translation. Expression of several microRNAs has been described to be altered in 
RASFs and to influence proliferation rates and production of pro-inflammatory cytokines and 
MMPs. Levels of miR-155 and miR-146a are constitutively elevated in cultured RASFs, as 
well as in RA synovial tissues, synovial fluid and PBMCs, whereas the expression of miR-
124a is decreased in RASFs compared to OASFs [44-48]. Expression of miR-203 is 
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constitutively upregulated in RASFs, and overexpression of miR-203 promotes production of 
IL-6 and MMPs in these cells [49]. Demethylation of normal synovial fibroblasts with 5-
azacytidine led to increased expression of miR-203, strongly suggesting that global 
hypomethylation in RASFs might be responsible for the upregulation of miR-203. As 
summarized in Figure 1, epigenetic changes can already potentially explain some of the key 
features of the imprinted phenotype of RASFs. However, more detailed analysis of epigenetic 
changes in RASFs is needed to enlighten direct connections of epigenetic changes and RASF 
behaviour and the stage of disease development when these epigenetic changes are induced. 
 
3.4 Do RASFs have an ‘inflammatory memory’? 
Constant activation of RASFs by inflammatory cytokines or danger signals may lead to 
modulation of signalling pathways via epigenetic mechanisms. This imprinting of a pro-
inflammatory state might not only aggravate the inflammatory state but also prevent 
resolution. For some signalling pathways with a known role in RA, modulating properties of 
the epigenetic machinery have already been described. NF-κB is recognized to play a major 
role in the regulation of inflammation and immune responses. The NF-κB family comprises 
five family members, namely p105-p50 (NF-κB1), p100-p52 (NF-κB2), p65 (RelA), RelB 
and c-Rel which can form different homo- and heterodimers. Upon cellular activation, 
inhibitor of κB (IκB), which is bound to the nuclear localization sequence of NF-κB, gets 
phosphorylated by IκB kinases (IKK) leading to IκB degradation. NF-κB then translocates to 
the nucleus and binds to consensus sequences in promoters of its target genes. HDACs and 
HATs are known to play multiple roles in the regulation of NF-kB activity. With its HAT 
activity, CBP/p300 regulates the transcriptional activity of NF-kB. P300/CBP increases NF-
kB transcriptional activation via acetylation of histone tails and recruitment of RNA 
polymerase II [50]. Accordingly HDAC3 represses NF-kB activity [51]. Also non-histone 
acetylation influences signalling by NF- kB. Acetylation of distinct NF-kB p65 lysines 
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promotes nuclear export of NF- kB by increasing its binding to IκB, or increases NF-κB DNA 
binding activity [51-53]. These examples of non-histone acetylation of p65 by p300/CBP 
underline the complexity of transcriptional control by acetylation. Interestingly, it was found 
that enhanced accessibility of NF-κB consensus sequences is also mediated by the MAPK p38 
pathway via induction of phosphorylation and phosphoacetylation of histone 3 [54]. This 
mechanism seems to be operative only in some NF-κB inducible genes, e.g. IL-8, but not in 
others like TNF-α, thereby enhancing NF-κB activated transcription selectively at specific 
loci.  
It seems that epigenetic mechanisms can not only directly influence gene expression, but in 
parallel modulate signalling pathways leading to perpetuation of a state of increased activity. 
In RASFs changes in gene expression and signalling pathways induced by activating signals 
might be imprinted after long cellular exposure to inflammatory stimuli, become independent 
of the activating stimulus, and persist even in its absence. Accordingly RASFs not only react 
to changes in the joint environment but also actively maintain inflammation and destruction 
independently of an inflammatory environment and thus are co-responsible for the persistent 
and destructive arthritis characterizing RA.  
 
4. Conclusion and summary 
Current knowledge of the etiopathogenesis of RA suggests that the development of RA is a 
multistep process whereby levels of pro-inflammatory cytokines and auto-antibodies are 
elevated years before onset, but additional triggers seem to be needed to finally initiate 
disease symptoms [1, 2]. Furthermore, the fact that even though current treatments quite 
successfully suppress disease activity, RA cannot be cured and symptoms will flare up after 
discontinuation of immune suppression, points to a permanently imprinted deregulation of 
involved cells. For a long time it has been recognized that RASFs differ in their phenotype 
from normal SFs and that their destructive behaviour has become imprinted and partly 
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independent of activating agents. The more we discover about epigenetic mechanisms the 
more plausible it becomes that in RASFs epigenetic changes might be responsible for the 
maintenance of the activated state of these cells. In combination with a specific genetic 
background that predisposes for a pathological immune response and environmental factors, 
the pathological preservation of synovial fibroblast activation by epigenetics might be the 
intrinsic local component that directs the inflammatory process towards the joints. Therefore, 
in addition to further elucidation of epigenetically altered pathways in RA, one of the main 
tasks for future research will be to find the cause for this destructive memorization of an 
inflammatory state.   
The concept that in predisposed individuals epigenetic changes lead to a pathological 
phenotype of stromal cells can be broadened to a variety of other chronic diseases. Among 
others a role for epigenetic changes has been suggested in the pathogenesis of Type 2 diabetes, 
chronic obstructive lung disease, chronic inflammatory bowel disease and atherosclerosis [55-
58]. Complex gene-environment interactions might alter immune function and inflammatory 
response via changes in the epigenome and thereby promote the development of chronic 
diseases. 
 
Take-home messages: 
• Synovial fibroblasts are key effectors cells in the pathogenesis of RA since they 
produce a wide variety of mediators of inflammation and joint destruction. 
• RASFs have an imprinted, activated phenotype that is independent of further 
activation by immune cells. 
• Epigenetic changes have been found to lead to changes in gene expression in RASFs 
and to shape the pathogenic phenotype of these cells. 
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Figure legend: 
Figure 1. Activation and epigenetic changes in RASFs. Constant activation of synovial 
fibroblasts by cytokines, pathogen-associated molecular patterns (PAMPs) or damage-
associated molecular patterns (DAMPs) via Toll-like or cytokine receptors might lead to 
modifications of transcription factors (e.g. MAPK, NF-kB), histone-deacetylases (e.g. 
HDAC4), histones or DNA and thereby the basal expression pattern of synovial fibroblasts in 
rheumatoid arthritis might be constitutively altered. Ph = phosphorylation; Ac = acetylation; 
Su = sumoylation; Me = methylation; TF = transcription factor. 
 
